The global oropharyngeal cancer diagnosis and therapeutics market are anticipated to grow at a considerable CAGR of 4.5% during the forecast period. The launch prices of new cancer drugs in the market have substantially increased in recent years despite growing concerns about the quantity and quality of evidence supporting their approval by the US Food and Drug Administration (FDA). For instance, in March 2022, the FDA approved Novartis’ Pluvicto, previously known as 177Lu-PSMA-617, for patients with metastatic castration-resistant prostate cancer (mCRPC) who test positive for the prostate-specific membrane antigen (PSMA) with an FDA-approved imaging diagnostic agent. Eligible patients must also have already tried an androgen receptor inhibitor and taxane-based chemotherapy.
A full report of Oropharyngeal Cancer Diagnosis and Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/oropharyngeal-cancer-diagnosis-and-therapeutics-market
Furthermore, in October 2021, Mayo Clinic researchers found a new treatment that employs minimally invasive surgery and half the standard dose of radiation therapy, compared to current treatments. The new treatment also lasts for two weeks, rather than the standard six weeks.
In February 2021, ‘Artificial Intelligence’ integrated PET-CT launched at Yashoda hospitals, Hyderabad on the occasion of world cancer day 2021. With the newly upgraded imaging of FDG PET-CT, the department provides advanced and rare imaging like Ga-68 DOTA, Ga-68 PSMA, 18F DOPA PET-CTs, DAT imaging & WBC scans, apart from routine Gamma imaging like bone scan & renal scintigraphy.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/oropharyngeal-cancer-diagnosis-and-therapeutics-market
Moreover, government initiatives to raise awareness are another key factor supporting the growth of the market. For instance, in April 2022, American Oncology Institute AOI launched a campaign to raise awareness about oral and mouth cancer, during ‘National Oral, Head and Neck Cancer Awareness Month’. The campaign aims to highlight the high-risk factors associated with all kinds of smokeless tobacco (STL) products while also making the viewers aware of the various preventive measures. It also focuses on the fact that emphasizes that smokeless tobacco products are not an alternative and are also harmful.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Diagnostic Type
o By Treatment Type
o By End-Users
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including AstraZeneca Plc, Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Co., GE Healthcare, Inovio Pharmaceuticals, Inc., and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Oropharyngeal Cancer Diagnosis and Therapeutics Market Report Segment
By Diagnostic Type
- Endoscopy
- Biopsy
- Imaging
- MRI Scan
- CT Scan
- PET-CT Scan
By Treatment Type
- Surgery
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Others
By End-Users
- Hospitals
- Ambulatory Surgery Centers
- Others
